Novo Hemophilia Drug's Postmarket Monitoring Plan Not Robust Enough – US Panel

FDA advisory committee members support approval of investigational hemophilia B treatment nonacog beta pegol but say Novo Nordisk needs more systematic approach to monitoring for neurological and developmental adverse events.